Director David L. Mahoney filed a Form 4 with the SEC on August 20, 2026, disclosing the sale of 103,606 shares of Corcept Therapeutics Inc common stock on August 18, 2026, executed under a pre-established 10b5-1 trading plan.

Key Highlights

  • Issuer and ticker: Corcept Therapeutics Inc, listed as NASDAQ:CORT
  • Total shares sold: 103,606 shares of common stock disposed of on August 18, 2026, across four separate tranches
  • Sale price range: Weighted average prices per tranche ranged from $117.4716 to $119.6381, with actual individual sale prices spanning $116.595 to $119.6775
  • Remaining beneficial ownership: 1,133,539 shares held indirectly through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, plus 26,147 shares held indirectly through The Black Dog Private Foundation
  • 10b5-1 plan: All sales were made pursuant to a plan adopted by the reporting person on May 11, 2026
  • Relationship to issuer: Mahoney is identified as a Director of Corcept Therapeutics Inc

David L. Mahoney's August 2026 Share Dispositions at Corcept Therapeutics

According to the filing, Director David L. Mahoney disposed of a total of 103,606 shares of Corcept Therapeutics Inc common stock on August 18, 2026. The sales were conducted in four tranches: 4,984 shares at a weighted average price of $117.4716, 91,167 shares at a weighted average price of $118.2376, 7,055 shares at a weighted average price of $118.8817, and 400 shares at a weighted average price of $119.6381. The filing notes that each weighted average price represents the average across a range of actual transaction prices within each tranche.

All shares were held and sold indirectly through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, according to the filing. The filing discloses that the transactions were made pursuant to a Rule 10b5-1 trading plan that Mahoney adopted on May 11, 2026. Following the reported transactions, the trust holds 1,133,539 shares of common stock. The filing also reports a separate indirect holding of 26,147 shares through The Black Dog Private Foundation, with no transactions reported against that position.

The Form 4 was signed by Joseph Douglas Lyon as attorney-in-fact for David L. Mahoney on August 20, 2026. The filing states that the power of attorney under which the form was signed is on file with the Commission. Exact share counts sold at each individual price point within each tranche are available from the issuer upon request, as noted in the filing's explanatory footnotes.

What Was Disclosed

The filing reports four open-market sales of Corcept Therapeutics common stock by Director David L. Mahoney on August 18, 2026, totaling 103,606 shares, all executed under a 10b5-1 plan adopted May 11, 2026, with shares held and sold through a family trust.